摘要
目的分析早发型子痫前期应用低分子肝素期待治疗的临床效果。方法回顾分析2017-01—2018-12间在郑州大学第一附属医院产科终止妊娠的95例早发型子痫前期患者的临床资料。按终止妊娠前是否应用低分子肝素分为2组。对照组(47例)给予降压、解痉等治疗;观察组(48例)在对照组基础上加用低分子肝素。结果2组分娩孕周、妊娠延长时间、妊娠并发症发生率、新生儿出生体质量、新生儿窒息及胎儿宫内窘迫发生率、新生儿Apgar评分等,差异均无统计学意义(P>0.05)。结论对早发型子痫前期患者在常规治疗基础上短期应用低分子肝素,不能延长妊娠时间,不改善母婴结局。
Objective To investigate the clinical effect of low molecular weight heparin(LMWH)on early onset preeclampsia.Methods From January 2017 to December 2018,Totally 95 patients with early onset preeclampsia who terminated pregnancy in our hospital were included in this study,and were divided into observation group(n=48)and control group(n=47)according to whether low molecular weight heparin was used before the termination of pregnancy.Patients in control group were treated with antihypensive and spasmolysis treatment,and in observation group low molecular weight heparin treatment was added.Results There were no significant differences in delivery gestational weeks,Prolonged pregnancy,incidence of pregnancy complications,neonatal birth weight,Apgar score,incidence of neonatal asphyxia and fetal intrauterine distress between the two groups(P>0.05).Conclusion The addition of low molecular weight heparin in the short term to the routine treatment of patients with early onset preeclampsia can not prolong the pregnancy time,and does not improve the maternal and infant outcomes.
作者
张文静
高丹丹
赵先兰
Zhang Wenjing;Gao Dandan;Zhao Xianlan(Department of Obstetrics,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《河南外科学杂志》
2020年第2期22-25,共4页
Henan Journal of Surgery
关键词
早发型子痫前期
低分子肝素
临床疗效
Early onset preeclampsia
Low molecular weight heparin
Clinical efficacy
